Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens

International Journal of Cancer

Volumn 115, Issue 5, 2005, Pages 752-759

  Mautner, Josef ^a,b   Jaffee, Elizabeth M ^a   Pardoll, Drew M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Immune response; MHC class II; Tumor antigen

Indexed keywords

CD4 ANTIGEN; GAMMA INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL IMMORTALIZATION; CELL LYSATE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; EPSTEIN BARR VIRUS; KIDNEY CARCINOMA; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR REGRESSION;

ANTIGENS, NEOPLASM; CANCER VACCINES; CARCINOMA, RENAL CELL; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; GENES, MHC CLASS II; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY TESTING; HUMANS; INTERFERON TYPE II; KIDNEY NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 20144364696     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20927     Document Type: Article

References (34)

1. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995;13:399-415.
2. Toes RE, Ossendorp F, Offringa R, Melief CJ. CD4 T cells and their role in antitumor immune responses. J Exp Med 1999;189: 753-6.
3. Pardoll DM, Topalian SL. The role of CD44+ T cell responses in antitumor immunity. Curr Opin Immunol 1998;10:588-94.
4. Wang RF, Rosenberg SA. Human tumor antigens for cancer vaccine development. Immunol Rev 1999;170:85-100.
5. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335:865-75.
6. Michael A, Pandha HS. Renal-cell carcinoma: tumor markers, T-cell epitopes, and potential for new therapies. Lancet Oncol 2003;4: 215-23.
7. Gaudin C, Kremer F, Angevin E, Scott V, Triebel F. A hsp70-2 mutation recognized by CTL on a human renal cell carcinoma. J Immunol 1999;162:1730-8.
8. Ronsin C, Chung-Scott V, Poullion I, Aknouche N, Gaudin C, Triebel F. A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. J Immunol 1999;163:483-90.
9. Vissers JL, De Vries IJ, Schreurs MW, Engelen LP, Oosterwijk E, Figdor CG, Adema GJ. The renal cell carcinoma-associated antigen G250 encodes a human leukocyte antigen (HLA)-A2.1-restricted epitope recognized by cytotoxic T lymphocytes. Cancer Res 1999;59: 5554-9.
10. Hanada K, Perry-Lalley DM, Ohnmacht GA, Bettinotti MP, Yang JC. Identification of fibroblast growth factor-5 as an overexpressed antigen in multiple human adenocarcinomas. Cancer Res 2001;61: 5511-6.
11. Van Den Eynde BJ, Gaugler B, Probst-Kepper M, Michaux L, Devuyst O, Lorge F, Weynants P, Boon T. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999;190: 1793-800.
12. Probst-Kepper M, Stroobant V, Kridel R, Gaugler B, Landry C, Brasseur F, Cosyns JP, Weynand B, Boon T, Van Den Eynde BJ. An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. J Exp Med 2001;193: 1189-98.
13. Kowalczyk D, Skorupski W, Kwias Z, Nowak J. Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma. Br J Urol 1997;80:543-7.
14. Van den Hove LE, Van Gool SW, Van Poppel H, Baert L, Coorevits L, Van Damme B, Ceuppens JL. Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma. Clin Exp Immunol 1997;109: 501-9.
15. Simons JW, Jaffee EM, Weber CE, Levitsky HI, Nelson WG, Carducci MA, Lazenby AJ, Cohen LK, Finn CC, Clift SM, Hauda KM, Beck LA, et al. Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. Cancer Res 1997;57:1537-46.
16. Jaffee EM, Dranoff G, Cohen LK, Hauda KM, Clift S, Marshall FF, Mulligan RC, Pardoll DM. High efficiency gene transfer into primary human tumor expiants without cell selection. Cancer Res 1993;53: 2221-6.
17. Jaffee EM, Schutte M, Gossett J, Morsberger LA, Adler AJ, Thomas M, Greten TF, Hruban RH, Yeo CJ, Griffin CA. Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. Cancer J Sci Am 1998;4:194-203.
18. Topalian SL, Rivoltini L, Mancini M, Ng J, Hartzman RJ, Rosenberg SA. Melanoma-specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by Epstein-Barr virus-transformed B cells. Int J Cancer 1994;58: 69-79.
19. Riddell SR, Greenberg PD. The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells. J Immunol Methods 1990;128:189-201.
20. Markus NR, Rosenberg SA, Topalian SL. Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes. J Interferon Cytokine Res 1995;15:739-46.
21. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73.
22. Topalian SL, Muul LM, Solomon D, Rosenberg SA. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods 1987;102:127-41.
23. Wang YC, Zhu L, McHugh R, Graham SD Jr, Hillyer CD, Dillehay D, Sell KW, Selvaraj P. Induction of autologous tumor-specific cytotoxic T-lymphocyte activity against a human renal carcinoma cell line by B7-1 (CD8O) costimulation. J Immunother Emphasis Tumor Immunol 1996;19:1-8.
24. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finke J. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 1997; 159:3057-67.
25. Urban RG, Chicz RM, Vignali DA, Strominger JL. The dichotomy of peptide presentation by class I and class II MHC proteins. Chem Immunol 1993;57:197-234.
26. Lechler R, Aichinger G, Lightstone L. The endogenous pathway of MHC class II antigen presentation. Immunol Rev 1996;151: 51-79.
27. Nimmerjahn F, Milosevic S, Behrends U, Jaffee EM, Pardoll DM, Bornkamm GW, Mautner J. Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy. Eur J Immunol 2003;33:1250-9.
28. Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64.
29. Robbins PF, El-Gamit M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 1996;183:1185-92.
30. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P. Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 1997;275:1790-2.
31. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
32. Rissoan MC, Soumelis V, Kadowaki N, Grouard G, Briere F, de Waal Malefyt R, Liu YJ. Reciprocal control of T helper cell and dendritic cell differentiation. Science 1999;283:1183-6.
33. Levitsky HI, Montgomery J, Ahmadzadeh M, Staveley-O'Carroll K, Guarnieri F, Longo DL, Kwak LW. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J Immunol 1996;156:3858-65.
34. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998;188:2357-68.